IP Library Granted Patent US 9,345,725
Granted Patent B2
US 9,345,725 · App. 11/722,618 · Granted May 24, 2016

Pharmaceutical formulations of gallium salts

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,345,725
App. No.
11/722,618
Granted
May 24, 2016
Kind
B2
Abstract

The present invention relates to pharmaceutical formulations containing a pharmaceutically acceptable gallium salt (such as gallium nitrate), a delivery agent, and optionally, one or more chemotherapeutic agents and/or adjunctive chemotherapeutic agents.

Claims (14)

1. An oral pharmaceutical composition comprising (a) gallium nitrate nonahydrate and (b) a delivery agent selected from N-(8-[2-hydroxybenzoyl]-amino)caprylic acid and pharmaceutically acceptable salts thereof.

2. The oral pharmaceutical composition of claim 1 , wherein the delivery agent is a sodium salt of N-(8-[2-hydroxybenzoyl]-amino)caprylic acid.

3. The pharmaceutical composition of claim 1 , wherein the pharmaceutical formulation provides sustained release of the gallium nitrate nonahydrate.

4. The pharmaceutical composition of claim 1 , wherein the pharmaceutical formulation, upon oral ingestion to a human, provides plasma gallium concentrations of about 0.1 to about 5 μg/ml.

5. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition, upon oral ingestion to a human, provides one or more of the following:

(a) plasma gallium concentrations of about 0.1 to about 5 μg/ml or about 0.9 to about 2.0 μg/ml,

(b) average steady state plasma levels of gallium from about 1000 to about 2500 ng/ml, or

(c) a decrease in serum calcium (corrected for albumin) of at least 2.0 mg/dl in a human with hypercalcemia (such as cancer-related hypercalcemia).

6. The oral pharmaceutical composition of claim 1 , wherein the weight ratio of delivery agent to gallium nitrate nonahydrate is about 3.6:1.

7. The oral pharmaceutical composition of claim 1 , comprising about 55 mg of gallium nitrate nonahydrate and about 200 mg of a delivery agent selected from N-(8-[2-hydroxybenzoyl]-amino)caprylic acid and pharmaceutically acceptable salts thereof.

8. A method of preparing an oral pharmaceutical composition comprising mixing a delivery agent selected from N-(8-[2-hydroxybenzoyl]-amino)caprylic acid and pharmaceutically acceptable salts thereof, gallium nitrate nonahydrate and, optionally, one or more pharmaceutically acceptable excipients or additives.

9. The method of claim 8 , wherein the weight ratio of delivery agent to gallium nitrate nonahydrate is about 3.6:1.

10. The method of claim 8 , wherein the oral pharmaceutical composition comprises about 55 mg of gallium nitrate nonahydrate and about 200 mg of a delivery agent selected from N-(8-[2-hydroxybenzoyl]-amino)caprylic acid and pharmaceutically acceptable salts thereof.

11. A method of treating hypercalcemia in a mammal in need thereof comprising orally administering to the mammal an effective amount of the pharmaceutical composition of claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2022
From: NOVO NORDISK NORTH AMERICA OPERATIONS A/S
To: NOVO NORDISK A/S
Reel/Frame 060352/0663 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2021
From: EMISPHERE TECHNOLOGIES, INC.
To: NOVO NORDISK NORTH AMERICA OPERATIONS A/S
Reel/Frame 056750/0169 →